Detalhe da pesquisa
1.
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
Clin Infect Dis
; 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305378
2.
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Ann Hematol
; 100(7): 1733-1742, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34018029
3.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(1): 43-56, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522969
4.
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Biol Blood Marrow Transplant
; 25(10): 2002-2007, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260802
5.
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Blood
; 130(21): 2243-2250, 2017 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28924018
6.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639149
7.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Blood
; 128(25): 2899-2908, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27802969
8.
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Haematologica
; 103(9): 1502-1510, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880603
9.
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol
; 93(11): 1402-1410, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129285
10.
Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.
Br J Haematol
; 177(4): 620-629, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28369718
11.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
12.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Pediatr Blood Cancer
; 63(2): 299-305, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26402148
13.
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Haematologica
; 105(4): e164-e168, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31413095
14.
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
J Pediatr Hematol Oncol
; 37(1): 1-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25493452
15.
Ibrutinib for Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(16): 1594-5, 2016 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27096594
16.
Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Haematologica
; 103(6): e249-e251, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29170253
17.
Red blood cell alloimmunization in sickle cell disease: prevalence in 2010.
Transfusion
; 53(4): 704-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22804353
18.
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
J Clin Oncol
; 41(10): 1876-1887, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608310
19.
Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE).
Br J Haematol
; 157(5): 627-36, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22463614
20.
Inpatient management of sickle cell pain: a 'snapshot' of current practice.
Am J Hematol
; 87(3): 333-6, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22231150